Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv Mice

• Cheryl A. Stoddart ,

  *To whom correspondence should be addressed. E-mail: cheryl.stoddart@ucsf.edu

  Current address: Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, California, United States of America,

  Affiliation Gladstone Institute of Virology and Immunology, University of California at San Francisco, San Francisco, California, United States of America

  ⨯
• Pheroze Joshi,

  Affiliation Gladstone Institute of Virology and Immunology, University of California at San Francisco, San Francisco, California, United States of America

  ⨯
• Barbara Sloan,

  Affiliation Gladstone Institute of Virology and Immunology, University of California at San Francisco, San Francisco, California, United States of America

  ⨯
• Jennifer C. Bare,

  Affiliation Gladstone Institute of Virology and Immunology, University of California at San Francisco, San Francisco, California, United States of America

  ⨯
• Philip C. Smith,

  Affiliation School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, United States of America

  ⨯
• Graham P. Allaway,

  Affiliation Panacos Pharmaceuticals, Gaithersburg, Maryland, United States of America

  ⨯
• Carl T. Wild,

  Current address: Gaithersburg, Maryland, United States of America

  Affiliation Panacos Pharmaceuticals, Gaithersburg, Maryland, United States of America

  ⨯
• David E. Martin

  Affiliation Panacos Pharmaceuticals, Gaithersburg, Maryland, United States of America

  ⨯